Novartis AG (NYSE:NVS) Shares Sold by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC reduced its stake in Novartis AG (NYSE:NVS) by 22.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,873 shares of the company’s stock after selling 2,911 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Novartis were worth $961,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Foundations Investment Advisors LLC boosted its position in Novartis by 26.9% during the 4th quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company’s stock valued at $8,668,000 after purchasing an additional 18,894 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Novartis by 115.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock valued at $26,797,000 after acquiring an additional 124,111 shares during the period. CWA Asset Management Group LLC grew its position in shares of Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock worth $3,001,000 after acquiring an additional 5,164 shares during the last quarter. Quantbot Technologies LP grew its position in shares of Novartis by 135.5% during the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after acquiring an additional 22,998 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of Novartis in the 4th quarter worth about $239,000. 13.12% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on NVS. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. BMO Capital Markets increased their price objective on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Finally, Erste Group Bank restated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Stock Up 0.3 %

Shares of NVS stock opened at $107.26 on Friday. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. The business’s fifty day moving average is $101.06 and its 200-day moving average is $108.15. The stock has a market cap of $219.23 billion, a PE ratio of 18.24, a price-to-earnings-growth ratio of 1.69 and a beta of 0.58.

Novartis (NYSE:NVS) last released its earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Equities analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.